Literature DB >> 7499440

Cytokines and bone marrow transplantation.

F Takaku1.   

Abstract

This article summarizes the various current uses of cytokines, and bone marrow and peripheral blood stem cell transplantation for cancer treatment. Interferons, interleukin-2 and hematopoietic growth factors are extensively used for the treatment of hematopoietic as well as nonhematopoietic malignancies, either as the main therapeutic agents or as an adjuvant. Research on gene therapy using cytokines is in progress. Stem cell transplantation is also discussed in the context of gene therapy of cancer. Gene therapy is expected to become a future modality in cancer treatment.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7499440     DOI： 10.1007/bf01213315

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


  79 in total

1.  Demonstration of stem cell inhibition and myeloprotective effects of SCI/rhMIP1 alpha in vivo.

Authors:  D J Dunlop; E G Wright; S Lorimore; G J Graham; T Holyoake; D J Kerr; S D Wolpe; I B Pragnell
Journal:  Blood       Date:  1992-05-01       Impact factor: 22.113

Review 2.  Autotransplants in chronic myelogenous leukaemia: strategies and results.

Authors:  A Butturini; A Keating; J Goldman; R P Gale
Journal:  Lancet       Date:  1990-05-26       Impact factor: 79.321

3.  Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

Authors:  M S Mitchell; R A Kempf; W Harel; H Shau; W D Boswell; S Lind; E C Bradley
Journal:  J Clin Oncol       Date:  1988-03       Impact factor: 44.544

Review 4.  Treatment of chronic myeloid leukemia by marrow transplantation.

Authors:  R A Clift; F R Appelbaum; E D Thomas
Journal:  Blood       Date:  1993-10-01       Impact factor: 22.113

5.  Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients.

Authors:  M K Brenner; D R Rill; M S Holladay; H E Heslop; R C Moen; M Buschle; R A Krance; V M Santana; W F Anderson; J N Ihle
Journal:  Lancet       Date:  1993-11-06       Impact factor: 79.321

6.  Erythropoietin treatment of anemia associated with multiple myeloma.

Authors:  H Ludwig; E Fritz; H Kotzmann; P Höcker; H Gisslinger; U Barnas
Journal:  N Engl J Med       Date:  1990-06-14       Impact factor: 91.245

7.  Decreased erythropoietin response in patients with the anemia of cancer.

Authors:  C B Miller; R J Jones; S Piantadosi; M D Abeloff; J L Spivak
Journal:  N Engl J Med       Date:  1990-06-14       Impact factor: 91.245

8.  Differential effects of sequential, simultaneous, and single agent interleukin-3 and granulocyte-macrophage colony-stimulating factor on megakaryocyte maturation and platelet response in primates.

Authors:  C P Stahl; E F Winton; M C Monroe; E Haff; R C Holman; L Myers; E Liehl; B L Evatt
Journal:  Blood       Date:  1992-11-15       Impact factor: 22.113

9.  Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma.

Authors:  M A Dimopoulos; J Hester; Y Huh; R Champlin; R Alexanian
Journal:  Br J Haematol       Date:  1994-08       Impact factor: 6.998

10.  Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia.

Authors:  M Talpaz; H M Kantarjian; K McCredie; J M Trujillo; M J Keating; J U Gutterman
Journal:  N Engl J Med       Date:  1986-04-24       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.